Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France

被引：0
|
作者：
M. Hiligsmann
J.-Y. Reginster
机构：
[1] Maastricht University,Department of Health Services Research, CAPHRI Care and Public Health Research Institute
[2] University of Liège,Department of Public Health, Epidemiology and Health Economics
[3] King Saud University,Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science
来源：
Osteoporosis International | 2019年 / 30卷
关键词：
Cost-effectiveness; Economic evaluation; Osteoporosis; Risedronate; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：649 / 658
页数：9
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF GASTRO-RESISTANT RISEDRONATE TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
    Hiligsmann, M.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S182 - S182
  • [2] Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
    Hiligsmann, M.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2019, 30 (03) : 649 - 658
  • [3] COST-EFFECTIVENESS OF ACTONEL® 35 MG (RISEDRONATE) GASTRO-RESISTANT TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE
    Hiligsmann, M.
    Reginster, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S298 - S298
  • [4] COST-EFFECTIVENESS OF WEEKLY GASTRO-RESISTANT RISEDRONATE 35 MG, COMPARED WITH WEEKLY ALENDRONATE TABLETS, IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN SPAIN
    Casado, E.
    Rosas, J. C.
    Aristegui, I.
    Rubio-Terres, C.
    Rubio-Rodriguez, D.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S333 - S333
  • [5] Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
    Casado, Enrique
    Rosas, Jose
    Rubio-Terres, Carlos
    Rubio-Rodriguez, Dario
    Boolell, Mitra
    Aristegui, Ignacio
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)
  • [6] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    J. A. Kanis
    F. Borgstrom
    O. Johnell
    B. Jonsson
    [J]. Osteoporosis International, 2004, 15 : 862 - 871
  • [7] Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women
    Kanis, JA
    Borgstrom, F
    Johnell, O
    Jonsson, B
    [J]. OSTEOPOROSIS INTERNATIONAL, 2004, 15 (11) : 862 - 871
  • [8] The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
    Hansheng Ding
    Nobuo Koinuma
    Matt Stevenson
    Michiya Ito
    Yasutake Monma
    [J]. Journal of Bone and Mineral Metabolism, 2008, 26 : 34 - 41
  • [9] The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis
    Ding, Hansheng
    Koinuma, Nobuo
    Stevenson, Matt
    Ito, Michiya
    Monma, Yasutake
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2008, 26 (01) : 34 - 41
  • [10] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S50 - S51
12345